Nirsum Labs Taps Lifecore Biomedical For CDMO Services In Clinical Development Of Novel Opioid Addiction Therapy

Lifecore Biomedical, Inc., a fully integrated CDMO, has been chosen by Nirsum Laboratories, Inc. to support the clinical development of Nirsum’s lead candidate, NRS-033. Under this agreement, Lifecore will assess and transfer the technology for the fill-and-finish procedure of NRS-033. Leveraging its specialized expertise in sterile injectable pharmaceuticals, Lifecore aims to develop a comprehensive plan for the entire fill-and-finish process, contributing to NRS-033’s development and potential commercialization.

Paul Josephs, chief executive officer of Lifecore, said in a statement, “With growing concerns about opioid and alcohol addiction in the U.S. and beyond, we’re grateful for the opportunity to support Nirsum on this important and promising treatment. Our agreement will enable Lifecore to apply our experience with complex formulations to the assessment, enhancement and validation of the fill and finish process for NRS-033. We are excited to add Nirsum to our growing list of customers and appreciative that their team has entrusted us to collaborate with them on these activities.”

NRS-033, a new treatment for opioid and alcohol use disorders, is owned and developed by Nirsum Laboratories. Currently advancing into Phase 2 clinical trials, NRS-033 will benefit from a partnership with Lifecore Biomedical. Under this agreement, Lifecore will supply filled syringes to support the clinical development of NRS-033.

Nikej Shah, M.D., chief executive officer of Nirsum Labs, also mentioned, “We believe that opioid and alcohol use disorders are enormous unmet needs, each with just a few decades-old, FDA-approved treatment options available. We believe NRS-033 will be a key innovation, solving the critical problem of short therapeutic retention of available therapies that results in high relapse rates for abstinence-seeking patients with OUD and AUD. By improving therapeutic retention with NRS-033, Nirsum aims to give hope to the millions of Americans with OUD and AUD. We are excited to begin our work with Lifecore to potentially help bring our important therapy through further clinical development and commercialization.”